OXFORD, Engeland–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) heeft vandaag aangekondigd dat Andrew Hopkins, DPhil., Exscientia’s oprichter en CEO, Ben Taylor, CFO & Chief Strategy Officer, en Garry Pairaudeau, Chief Technology Officer, zullen deelnemen aan een fireside chat op de Evercore ISI 4e jaarlijkse HealthCONx virtuele conferentie op donderdag 2 december 2021 om 10:30 uur ET (15:30 uur GMT).

Een live webcast van de fireside chat zal beschikbaar zijn op de website van het bedrijf, onder de sectie “Investors & Media” op investor.exscientia.ai. Een gearchiveerde herhaling van de webcast zal ongeveer 30 dagen na de presentatie beschikbaar zijn.

Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005432/en/

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
Amanda Galgay

media@exscientia.ai